Navigation Links
Lung cancers detected by CT screening grow as fast as those found with traditional methods
Date:3/30/2012

A new study led by researchers at Mount Sinai School of Medicine indicates that CT scans are more effective than traditional lung cancer detection methods at identifying aggressive lung cancers in their most treatable stages. The data, published online March 27 in the journal Radiology, demonstrate that lung cancers found through annual CT screening are similar to those found in routine practice, both in terms of tumor growth rates and cell-type distribution. In fact, the report showed that 79 percent of the cases diagnosed through annual repeat CT scans were detected at clinical Stage I, the earliest and most treatable stage, compared to only 15 percent detected through traditional methods.

The study, which is the latest report from the International Early Lung Cancer Action Program (I-ELCAP), counters concerns that lung cancers diagnosed through annual repeat rounds of computed tomography (CT) screening may be of less serious varieties than those diagnosed in traditional clinical settings when symptoms are already present.

"We've previously shown that, similar to common screening methods such as mammography for breast cancer, annual CT scans are effective in early detection of lung cancer. However, there were concerns that the cancer found in these screenings were less serious than those found in routine practice in the clinical setting, and often resulted in excessive treatment," said Claudia I. Henschke, PhD, MD, Professor of Radiology at Mount Sinai School of Medicine and I-ELCAP principal investigator. "However, the data show that lung cancers detected with annual repeat rounds of CT scans are just as lethal and require equally aggressive treatment."

I-ELCAP is an international collaborative group of more than 60 participating institutes consisting of experts on lung cancer related diseases. Previous research from the group found that lung cancers detected through CT screening have an 80 percent cure rate compared to a 10 percent cure rate for lung cancers detected in the clinical setting.

"Lung cancer is by far the leading cause of cancer death among both men and women. However, when lung cancer is caught in an early, treatable stage, the cure rates are significantly higher," said Dr. Henschke. "It is recommended that people at high risk for lung cancer speak with their health care provider to discuss the benefits and risks of screening in order to make an informed decision about enrolling in a screening program."

Lung cancer accounts for more annual deaths than colon, breast, and prostate cancers combined. The American Cancer Society estimates that in 2012, approximately 226,160 new cases of lung cancer will be diagnosed in the United States and 160,340 Americans will die from the disease.

For this study, the researchers reviewed pooled results from the I-ELCAP database for 1993 to 2009, consisting of men and women at risk for lung cancer who underwent annual repeat rounds of CT screening. Researchers found 111 cases of lung cancer, 90 of which were non-small-cell cancers. Out of the 111 cases, 79 percent were clinical Stage I, the earliest and most treatable stage. Non-small-cell lung cancer is the most common form of lung cancer.

The researchers then compared their findings to a 2008 study published in the Journal of Thoracic Oncology analyzing the growth rates of non-small-cell lung cancers detected through traditional methods. The 2008 study found that only about 15 percent of those cancers were discovered in Stage I.

The researchers also found that while the first round of CT screening detected a higher proportion of slower-growing cancers than those detected in clinical practice, the subsequent annual repeat rounds of screening reflected what is found in clinical practice.

The investigators then analyzed volume doubling time or growth rate and cell-type distribution of the cancers. The mean volume doubling time for all cases was 136 days. Volume doubling times for lung cancers diagnosed in clinical practice ranged from 20 to 360 days. For the 90 non-small-cell cancers, mean volume doubling time was 154 days compared to 135 days in the 2008 study.

When researchers evaluated the cell-types of the cancers, they found the frequencies of small-cell carcinoma, which usually develops in the central areas of the lung, and adenocarcinoma, usually located on the outer surface of the lungs, to be approximately 19 percent and 50 percent, respectively. In the 2008 study these frequencies were nearly identical, at 20 percent and 50 percent.

In addition, the researchers found that 89 percent of the cancers that manifested as solid nodules had significantly faster volume doubling times than the sub-solid nodule cancers and may need a less aggressive diagnosis and treatment approach. The researchers defined cancerous nodules as solid if they obscured all of the lung tissue and sub-solid if they did not.

"Identifying the varying growth rates for specific lesion types should allow us to create a more tailored treatment for the patient," said Dr. Henschke.


'/>"/>

Contact: Mount Sinai Medical Center Press Office
NewsMedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Genes Play Role in Prognosis With Non-Small Cell Lung Cancers
2. Researchers chart genomic map spanning over 2 dozen cancers
3. Scientists Spot Genetic Fingerprints of Individual Cancers
4. Accelerated radiation therapy reduces toxicity in patients with advanced head and neck cancers
5. Proton beam therapy shows encouraging long-term outcome for patients with locally advanced sinonasal cancers
6. Herceptin and Tykerb effective against a subset of gastric cancers
7. Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium
8. Exploiting the architecture of cancers may lead to their destruction
9. Palpable breast cancers are more common in women not undergoing annual mammography
10. Non-Melanoma Skin Cancers in the Millions and Rising
11. Virtual colonoscopy allows detection of unsuspected cancers beyond colon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , ... April 24, 2017 , ... Rod Burkett, CEO ... Housing News website. , Rod has been at the forefront of Gardant since it ... As CEO, Rod has overseen the opening of more than 40 new senior living ...
(Date:4/24/2017)... Switzerland (PRWEB) , ... April 24, 2017 , ... ... steps to become familiar. This makes it difficult for lab operators and management ... systematic methodology to help them identify wasteful or unnecessary actions. , Created ...
(Date:4/24/2017)... ... ... to Use Your SPIRITUAL COMPASS To Navigate Life Issues”: a guide to using the ... Issues” is the creation of published author, Rachel Jamerson, writer of 25 years, Crisis ... and former member of the American Association of Christian Counselors. Rachel studied accounting ...
(Date:4/24/2017)... and Seattle, WA (PRWEB) , ... April 24, ... ... by 75+ leading lifestyle brands, work wear distributors and International relief organizations across ... can carry. The company also offers lifestyle and work wear collections via ...
(Date:4/23/2017)... ... April 23, 2017 , ... Altura Communication ... achievement of Cisco Select certification and SMB specialization. Altura is now qualified ... , In earning the Select Certification, Altura fulfilled the training and exam requirements ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  Vivify Health, the pioneer and market ... awarded a very significant patent for the advancement of ... care via digital health.  This landmark patent provides the ... further secures Vivify,s position as the leader in remote ... the first company to apply consumer mobile devices, wireless ...
(Date:4/20/2017)... -- Research and Markets has announced the addition of ... Expanding Injectables Market and Increasing Usage of Complex Biologics during the ... ... from USD 20 Billion in 2015 to around USD 26 Billion ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2014 ... ... US$ 7,167.6 Mn in 2015, and is expected to reach ... 5.6% from 2016 to 2024. The global ...
Breaking Medicine Technology: